THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY |For Healthcare Professionals

Why SUTAB® ?

NOW YOU HAVE A CHOICE WITH A NEW TABLET FOR BOWEL PREPARATION

dose-kit

Tablets and packaging not shown actual size.

TABLET
INTRODUCING
  1. NO SODIUM PHOSPHATE2
  2. SAFE AND EFFECTIVE1,2
  3. ACG-RECOMMENDED SPLIT-DOSE REGIMEN4
    • Two SUTAB doses are required for a complete preparation2
    • Dose 1 consists of 12 tablets and 16 oz of water
    • Dose 2 consists of 12 tablets and 16 oz of water
    • Each dose is followed by two additional 16 oz of water
Braintree Laboratories
Braintree Laboratories

Trusted makers of quality bowel preparations for over 35 years

IMPORTANT SAFETY INFORMATION

INDICATION
SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

DOSAGE AND ADMINISTRATION
A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy.

CONTRAINDICATIONS
Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention.

WARNINGS AND PRECAUTIONS
Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use. Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold. Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing. Suspected GI obstruction or perforation: Rule out the diagnosis before administration.

ADVERSE REACTIONS
Most common gastrointestinal adverse reactions are nausea, abdominal distension, vomiting, and upper abdominal pain.

DRUG INTERACTIONS
Drugs that increase risk of fluid and electrolyte imbalance.

View the Full Prescribing Information and Medication Guide.

References: 1. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. Published online November 6, 2020. doi: 10.14309/ajg.0000000000001020. 2. SUTAB® [package Insert]. Braintree, MA: Braintree Laboratories, Inc; 2020. 3. IQVIA. National Prescription Audit Report. November 2020. 4. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 (corrected). Am J Gastroenterol. 2009;104(3):739-750.